Overview

L19TNFα in Patients With Advanced Solid Tumors

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

The recombinant human fusion protein L19TNFα was created with the intention to overcome the systemic toxicity of TNFα by directly targeting it to tumor tissues. Tumor-targeted L19TNFα would result in high and sustained intralesional bioactive TNFα concentrations.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Philogen S.p.A.

Collaborators:

Eudax S.r.l.
InnoPharma Inc.